TrialActa dermato-venereologica2026

Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons.

Yangfeng Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.